Pelthos Therapeutics Files 8-K for Reg FD Disclosure

TL;DR

Pelthos Therapeutics filed an 8-K for a Reg FD disclosure on 10/14/25.

AI Summary

Pelthos Therapeutics Inc. filed an 8-K on October 14, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself.

Why It Matters

This filing indicates Pelthos Therapeutics Inc. is making a public disclosure under Regulation FD, which ensures all investors receive the same material information simultaneously.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure and does not contain information about significant financial changes, operational risks, or strategic shifts.

Key Players & Entities

• Pelthos Therapeutics Inc. (company) — Registrant
• October 14, 2025 (date) — Date of earliest event reported
• Regulation FD (regulation) — Type of disclosure
• Nevada (jurisdiction) — State of incorporation
• 4020 Stirrup Creek Drive, Suite 110 Durham, NC 27703 (address) — Principal executive office

FAQ

From the Filing

0001753926-25-001606.txt : 20251014 0001753926-25-001606.hdr.sgml : 20251014 20251014074612 ACCESSION NUMBER: 0001753926-25-001606 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20251014 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20251014 DATE AS OF CHANGE: 20251014 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pelthos Therapeutics Inc. CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 251389684 BUSINESS ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-908-2422 MAIL ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: Channel Therapeutics Corp DATE OF NAME CHANGE: 20241118 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 8-K 1 g084975_8k.htm 8-K false 0001919246 0001919246 2025-10-14 2025-10-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 14, 2025   Pelthos Therapeutics Inc.   (Exact name of registrant as specified in its charter)   Nevada   001-41964   86-3335449 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   4020 Stirrup Creek Drive , Suite 110 Durham , NC   27703 (Address of registrant’s principal executive office)   (Zip code)   Registrant’s telephone number, including area code: (919) 908-2400   (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   PTHS   The NYSE American LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 7.01. Regulation FD Disclosure.   On October 14, 2025, Pelthos Therapeutics Inc. (the “Company”) made available a presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.1. Information contained on the Company’s website is not incorporated by reference into and should not be considered to be part of this Curre